Investor Alert

New York Markets Close in:

June 15, 2021, 8:42 a.m. EDT

Ocugen's stock is up 14% after announcing manufacturing partner for experimental COVID-19 shot

Shares of Ocugen Inc. (NAS:OCGN) gained 14.3% in premarket trading on Tuesday after the company said it picked Jubilant HollisterStier, a privately held pharmaceutical contract manufacturer, to produce its still-investigational COVID-19 vaccine for the U.S. and Canada. The vaccine is not authorized or approved in either country at this time. Ocugen's stock is up 239.4% so far this year, while the broader S&P 500 (S&P:SPX) has gained 13.3%.

Link to MarketWatch's Slice.